Maze Therapeutics Executive Stock Transaction Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 22 2026
0mins
Should l Buy MAZE?
Source: Fool
- Executive Stock Transaction: On March 10, 2026, Maze Therapeutics' Chief Medical Officer Harold Bernstein exercised 30,000 stock options and immediately sold them for approximately $1.51 million, reflecting executive confidence in the company's future.
- Ownership Change: Following this transaction, Bernstein's direct stock holdings were reduced from 30,000 shares to zero; however, he still retains 267,407 stock options, indicating ongoing potential economic interest in the company.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, which allows insiders to sell shares at predetermined dates, ensuring transparency and compliance, thereby alleviating market concerns regarding the motivations behind the sale.
- Market Performance: Maze Therapeutics' stock has shown remarkable resilience, increasing for 11 consecutive months since its IPO, although investors should remain cautious of potential short-term volatility ahead of the upcoming Q4 earnings report for fiscal year 2025 scheduled for April 6.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.050
Low
46.00
Averages
52.00
High
60.00
Current: 29.050
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Investigation into Potential Claims for Maze Therapeutics Investors
- Clinical Trial Results: On March 25, 2026, Maze Therapeutics announced topline results from its Phase 2 HORIZON trial, showing that MZE829 achieved a mean reduction of approximately 35.6% in urine albumin-to-creatinine ratio (uACR) at Week 12, with about 50% of patients experiencing over a 30% reduction, which the company characterized as 'clinically meaningful'.
- Stock Price Plunge: Following the announcement of these clinical results, Maze's stock price declined by approximately 33% on March 25, 2026, indicating a negative market reaction that could lead to significant losses for investors.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Maze's executives complied with federal securities laws, particularly regarding potential improper disclosures following the stock price drop, aiming to seek compensation for affected investors.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
- Executive Stock Transaction: Harold Bernstein, the CMO of Maze Therapeutics, exercised 15,000 stock options and immediately sold the shares for approximately $736,000, indicating a strategy of utilizing options for liquidity rather than reducing existing stock positions.
- Market Reaction: Despite Maze Therapeutics reporting positive topline data from the Phase 2 HORIZON Trial of MZE829, the stock plummeted 33% on Wednesday, reflecting market sensitivity to executive stock sales and potential liquidity events.
- Significant Clinical Progress: MZE829 demonstrated a 35.6% reduction in proteinuria in clinical trials, with half of the patients achieving at least a 30% reduction, indicating potential for delaying disease progression and strong efficacy in certain subgroups.
- Long-term Investment Outlook: While the stock experiences short-term volatility, the progress in Maze Therapeutics' pipeline and its focus on genetically validated small molecule drugs provide a solid foundation for future commercialization, suggesting a favorable outlook for long-term investors.
See More
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
- Clinical Trial Data: Maze Therapeutics reported 12-week data from its HORIZON study showing that MZE829 led to a clinically meaningful decline in proteinuria, with an average uACR reduction of 35.6% among 12 patients, indicating potential efficacy in treating APOL1-mediated kidney disease.
- Safety Analysis: The safety analysis involving 15 patients indicated that MZE829 was well tolerated, with common treatment-related adverse events including headache and diarrhea, and no serious adverse events reported, highlighting the drug's safety profile.
- Market Reaction: Despite the encouraging initial data, Maze Therapeutics' stock plummeted approximately 37%, reflecting market concerns about the company's future prospects, possibly linked to investor interpretation of the clinical trial results.
- Financial Position: Ahead of the trial readout, Maze Therapeutics reported its Q4 2025 financial results, indicating a cash runway extending into 2028, which underscores the company's financial stability amidst ongoing clinical developments.
See More
Maze Therapeutics Reports Positive Phase 2 Data for MZE829 in Kidney Disease
- Clinical Trial Results: Maze Therapeutics' Phase 2 HORIZON trial for MZE829 demonstrated a clinically meaningful 35.6% mean reduction in proteinuria at week 12 among broad APOL1-mediated kidney disease patients, with 50% achieving over 30% reduction, indicating significant potential for improving renal function.
- Patient Group Analysis: The trial enrolled 15 patients, all included in safety and tolerability assessments, with FSGS patients showing a remarkable 61.8% mean reduction in uACR, highlighting MZE829's strong efficacy in specific subgroups.
- Future Development Plans: Maze intends to continue patient enrollment in the HORIZON trial and advance MZE829 into pivotal clinical programs, aiming to provide new treatment options for broad APOL1-mediated kidney disease patients and solidify its position in the biopharmaceutical sector.
- Market Reaction: In pre-market trading on Wednesday, Maze Therapeutics' stock rose 9.45% to $53.63, reflecting positive market sentiment towards the clinical data for MZE829, which may drive future financing and R&D activities.
See More
Maze Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q4 GAAP EPS of -$0.65, beating expectations by $0.07, indicating resilience in financial performance despite ongoing losses.
- Strong Cash Reserves: The company holds $360 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years with an expected cash runway extending into 2028, which boosts investor confidence.
- Innovative Platform: With its nature-driven innovative platform, Maze Therapeutics is focused on developing new therapies, showcasing potential in the biopharmaceutical sector that may attract increased investor interest in its R&D progress.
- Positive Market Reaction: Following the earnings release, the market reacted positively to Maze Therapeutics, enhancing investor confidence in its future growth potential, which could lead to an increase in stock price.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Investigation into Potential Claims for Maze Therapeutics Investors
- Clinical Trial Results: On March 25, 2026, Maze Therapeutics announced topline results from its Phase 2 HORIZON trial, showing that MZE829 achieved a mean reduction of approximately 35.6% in urine albumin-to-creatinine ratio (uACR) at Week 12, with about 50% of patients experiencing over a 30% reduction, which the company characterized as 'clinically meaningful'.
- Stock Price Plunge: Following the announcement of these clinical results, Maze's stock price declined by approximately 33% on March 25, 2026, indicating a negative market reaction that could lead to significant losses for investors.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Maze's executives complied with federal securities laws, particularly regarding potential improper disclosures following the stock price drop, aiming to seek compensation for affected investors.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
- Executive Stock Transaction: Harold Bernstein, the CMO of Maze Therapeutics, exercised 15,000 stock options and immediately sold the shares for approximately $736,000, indicating a strategy of utilizing options for liquidity rather than reducing existing stock positions.
- Market Reaction: Despite Maze Therapeutics reporting positive topline data from the Phase 2 HORIZON Trial of MZE829, the stock plummeted 33% on Wednesday, reflecting market sensitivity to executive stock sales and potential liquidity events.
- Significant Clinical Progress: MZE829 demonstrated a 35.6% reduction in proteinuria in clinical trials, with half of the patients achieving at least a 30% reduction, indicating potential for delaying disease progression and strong efficacy in certain subgroups.
- Long-term Investment Outlook: While the stock experiences short-term volatility, the progress in Maze Therapeutics' pipeline and its focus on genetically validated small molecule drugs provide a solid foundation for future commercialization, suggesting a favorable outlook for long-term investors.
See More
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
- Clinical Trial Data: Maze Therapeutics reported 12-week data from its HORIZON study showing that MZE829 led to a clinically meaningful decline in proteinuria, with an average uACR reduction of 35.6% among 12 patients, indicating potential efficacy in treating APOL1-mediated kidney disease.
- Safety Analysis: The safety analysis involving 15 patients indicated that MZE829 was well tolerated, with common treatment-related adverse events including headache and diarrhea, and no serious adverse events reported, highlighting the drug's safety profile.
- Market Reaction: Despite the encouraging initial data, Maze Therapeutics' stock plummeted approximately 37%, reflecting market concerns about the company's future prospects, possibly linked to investor interpretation of the clinical trial results.
- Financial Position: Ahead of the trial readout, Maze Therapeutics reported its Q4 2025 financial results, indicating a cash runway extending into 2028, which underscores the company's financial stability amidst ongoing clinical developments.
See More
Maze Therapeutics Reports Positive Phase 2 Data for MZE829 in Kidney Disease
- Clinical Trial Results: Maze Therapeutics' Phase 2 HORIZON trial for MZE829 demonstrated a clinically meaningful 35.6% mean reduction in proteinuria at week 12 among broad APOL1-mediated kidney disease patients, with 50% achieving over 30% reduction, indicating significant potential for improving renal function.
- Patient Group Analysis: The trial enrolled 15 patients, all included in safety and tolerability assessments, with FSGS patients showing a remarkable 61.8% mean reduction in uACR, highlighting MZE829's strong efficacy in specific subgroups.
- Future Development Plans: Maze intends to continue patient enrollment in the HORIZON trial and advance MZE829 into pivotal clinical programs, aiming to provide new treatment options for broad APOL1-mediated kidney disease patients and solidify its position in the biopharmaceutical sector.
- Market Reaction: In pre-market trading on Wednesday, Maze Therapeutics' stock rose 9.45% to $53.63, reflecting positive market sentiment towards the clinical data for MZE829, which may drive future financing and R&D activities.
See More
Maze Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q4 GAAP EPS of -$0.65, beating expectations by $0.07, indicating resilience in financial performance despite ongoing losses.
- Strong Cash Reserves: The company holds $360 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years with an expected cash runway extending into 2028, which boosts investor confidence.
- Innovative Platform: With its nature-driven innovative platform, Maze Therapeutics is focused on developing new therapies, showcasing potential in the biopharmaceutical sector that may attract increased investor interest in its R&D progress.
- Positive Market Reaction: Following the earnings release, the market reacted positively to Maze Therapeutics, enhancing investor confidence in its future growth potential, which could lead to an increase in stock price.
See More
